Rebus Pharmaceutical Llp
Imports, exports, and sells various pharmaceutical and healthcare products globally.
2016 | Kolkata, West Bengal (India) | Active
Rebus Pharmaceutical Llp Profile
Key Indicators
- Obligation of Contribution ₹ 0.10 M
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
About Rebus Pharmaceutical Llp
Rebus Pharmaceutical Llp (RPL) is 8 Year, 8 Months old Limited Liability Partnership 09 June 2016. Its registered office is in Kolkata, West Bengal, India.
The LLP status is Active, and it has filed its Accounts and Solvency Statement up to 31 Mar 2023 (FY 2022-2023). It's Total Obligation of Contribution is Rs 0.10 M as per MCA.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN/FCRN
AAG-6149
- Incorporation Date
09 Jun 2016
- Date of Accounts and Solvency Statement
31 Mar 2023
- ROC Code
Roc-Kolkata
- Company Classification
Limited Liability Partnership
Industry
Pharma
What products or services does Rebus Pharmaceutical Llp offer?
Rebus Pharmaceutical Llp offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit, Pulse Oximeter, Glucometer & POCT Devices, Pulse Oximeter, Rapid Antigen Test Kit, Covid Antibody Test Kit, ECG Accessories, ECG Holter Monitor.
Who are the key members and board of directors at Rebus Pharmaceutical Llp?
Designated Partners (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bina Damani  | Designated Partner | 09-Jun-2016 | Current |
| Mayank Damani | Designated Partner | 09-Jun-2016 | Current |
Financial Performance of Rebus Pharmaceutical Llp.
Enhance accessibility to Rebus Pharmaceutical Llp's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rebus Pharmaceutical Llp?
Unlock access to Rebus Pharmaceutical Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Staark Stock Vision Llp
Bina Damani is a mutual person
Charges (Loans)
There are no Open Charges registered against the LLP as per our records.
How Many Employees Work at Rebus Pharmaceutical Llp?
Unlock and access historical data on people associated with Rebus Pharmaceutical Llp, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rebus Pharmaceutical Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rebus Pharmaceutical Llp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.